305 related articles for article (PubMed ID: 20591786)
1. [Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].
Lengyel G; Fehér J
Orv Hetil; 2010 Jul; 151(29):1177-81. PubMed ID: 20591786
[TBL] [Abstract][Full Text] [Related]
2. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.
Ishikawa T
World J Gastroenterol; 2008 Oct; 14(40):6140-4. PubMed ID: 18985803
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of interferon-based therapy for chronic hepatitis C.
Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
[TBL] [Abstract][Full Text] [Related]
5. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.
Masuzaki R; Yoshida H; Omata M
Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579
[TBL] [Abstract][Full Text] [Related]
6. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
7. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
[TBL] [Abstract][Full Text] [Related]
8. [Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma].
Pár A
Orv Hetil; 2009 Jan; 150(1):19-26. PubMed ID: 19091671
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
10. Role of antiviral therapy in the management of hepatocellular carcinoma.
Guan YS; He Q
Anticancer Drugs; 2013 Apr; 24(4):337-43. PubMed ID: 23388161
[TBL] [Abstract][Full Text] [Related]
11. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Kim BK; Han KH; Ahn SH
Oncology; 2011; 81 Suppl 1():41-9. PubMed ID: 22212935
[TBL] [Abstract][Full Text] [Related]
12. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Triolo M; Della Corte C; Colombo M
Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
[TBL] [Abstract][Full Text] [Related]
13. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
Stournaras E; Neokosmidis G; Stogiannou D; Protopapas A; Tziomalos K
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1277-1282. PubMed ID: 30179906
[TBL] [Abstract][Full Text] [Related]
14. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
Khokhar N; Niazi TK; Qureshi MO
J Coll Physicians Surg Pak; 2013 Oct; 23(10):699-702. PubMed ID: 24112253
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of chronic hepatitis B virus infection and hepatocellular carcinoma prevention].
Soudan D; Sultanik P; Pol S
Presse Med; 2015 Dec; 44(12 Pt 1):1251-5. PubMed ID: 26358671
[TBL] [Abstract][Full Text] [Related]
17. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
18. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.
Osaki Y; Ueda Y; Marusawa H; Nakajima J; Kimura T; Kita R; Nishikawa H; Saito S; Henmi S; Sakamoto A; Eso Y; Chiba T
J Gastroenterol; 2012 Apr; 47(4):444-51. PubMed ID: 22105231
[TBL] [Abstract][Full Text] [Related]
19. Does antiviral therapy prevent hepatocellular carcinoma?
Kwon H; Lok AS
Antivir Ther; 2011; 16(6):787-95. PubMed ID: 21900710
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after interferon therapy in patients with chronic hepatitis C.
Buti M; Esteban R
Ann Hepatol; 2007; 6(4):267-9. PubMed ID: 18007558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
